Antifungal drug itraconazole tested for lung disease with mold

NCT ID NCT07283497

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing whether the antifungal drug itraconazole is feasible and safe for people with bronchiectasis who have mold growing in their airways. Thirty participants will take itraconazole twice daily for six weeks. The study will measure how many people complete treatment, side effects, and changes in breathing symptoms and airway bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Itraconazole (an antifungal medication taken by mouth)
What this could lead to: If successful, this could point toward a new treatment option for bronchiectasis patients with mold in their airways, potentially improving symptoms and quality of life.
What could go wrong: This is a very small, early pilot study with only 30 participants, so results may not apply to everyone. Itraconazole can cause liver side effects, and the drug may not be well tolerated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIECTASIS FUNGAL INFECTION OF UPPER RESPIRATORY TRACT

Contacts and locations

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.